Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.63 |
| ▸ | FYN | P06241 | 4/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.50 |
| ▸ | PIM1 | P11309 | 4/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | SYK | P43405 | 1/20 | 0.47 |
| ▸ | MMP13 | P45452 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12699555 | 0.91 | FYN (0.63) | MKNK1FYNKCNH2PIM1POLB | |
| SCHEMBL3033422 | 0.90 | MKNK1 (0.68) | MKNK1FYNKCNH2PIM1POLB | |
| SCHEMBL12350891 | 0.88 | FYN (0.52) | MKNK1FYNKCNH2PIM1POLB | |
| SCHEMBL2941615 | 0.88 | FYN (0.51) | MKNK1FYNPIM1SYKALDH1A1 | |
| SCHEMBL2356723 | 0.86 | PIM1 (0.49) | MKNK1FYNKCNH2PIM1POLB | |
| SCHEMBL2237814 | 0.86 | PIM1 (0.47) | MKNK1FYNKCNH2PIM1POLB | |
| SCHEMBL12699340 | 0.86 | FYN (0.52) | MKNK1FYNKCNH2PIM1POLB | |
| SCHEMBL3046484 | 0.86 | MKNK1 (0.71) | MKNK1FYNKCNH2PIM1 | |
| SCHEMBL3031328 | 0.86 | MKNK1 (0.64) | MKNK1FYNKCNH2PIM1 | |
| SCHEMBL3031333 | 0.86 | MKNK1 (0.64) | MKNK1FYNKCNH2PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216798-A1 | FUSED HETEROCYCLES AS LCK INHIBITORS | ASTELLAS PHARMA INC (JP) | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216798-A1 | FUSED HETEROCYCLES AS LCK INHIBITORS | LCK, ZAP70, FYN | MKNK1 816/4885FYN 3/4885KCNH2 235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.